FIELD: biotechnology.
SUBSTANCE: invention relates to a non-human animal for the expression of a human albumin protein, comprising in its genome a humanized endogenous albumin locus, in which the endogenous albumin locus region from the start codon to the stop codon is removed and is replaced by the corresponding human albumin sequence containing the region from the start codon to the stop codon of the human albumin gene, to its cell, as well as to a method of producing said animal.
EFFECT: invention is effective for assessing the activity of the reagent targeting human albumin, as well as for selecting a method which provides higher activity of the reagent targeting human albumin.
50 cl, 11 dwg, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CAS-EXPRESSING MOUSE EMBRYONIC STEM CELLS, AND MICE AND THEIR USE | 2018 |
|
RU2782358C2 |
| ANIMALS OTHER THAN HUMAN, INCLUDING HUMANIZED TTR LOCUS, AND APPLICATION METHODS | 2018 |
|
RU2784927C1 |
| MICE CONTAINING MUTATIONS, AS A RESULT OF WHICH FIBRILLIN-1 SHORTENED AT C-TERMINUS IS EXPRESSED | 2017 |
|
RU2721125C1 |
| NON-HUMAN ANIMALS CONTAINING THE HUMANIZED ASGR1 LOCUS | 2018 |
|
RU2796949C2 |
| METHODS AND COMPOSITIONS FOR ASSESSMENT OF MEDIATED CRISPR/CAS DESTRUCTION OR CUTOUT AND INDUCED CRISPR/CAS RECOMBINATION WITH EXOGENEOUS DONOR NUCLEIC ACID IN VIVO | 2018 |
|
RU2782356C2 |
| NON-HUMAN ANIMALS CONTAINING THE HUMANIZED TrkB LOCUS | 2018 |
|
RU2800428C2 |
| ANIMALS OTHER THAN HUMANS CHARACTERIZED IN EXPANSION OF HEXANUCLEOTIDE REPEATS AT LOCUS C9orf72 | 2017 |
|
RU2760877C2 |
| NON-DESTRUCTIVE GENE THERAPY FOR TREATING MMA | 2018 |
|
RU2820602C2 |
| CRISPR/CAS PLATFORM FOR EXCLUSIVE SCREENING FOR DETECTING GENETIC VULNERABILITIES ASSOCIATED WITH TAU PROTEIN AGGREGATION | 2020 |
|
RU2808829C2 |
| NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
